PacBio (PACB) announced SPRQ, an improved sequencing chemistry for its Revio long-read sequencing system. The new chemistry will reduce Revio DNA input requirements by 4x to 500ng per sample, which enables more sample types such as saliva extracted with PacBio’s new Nanobind protocol and tumor samples to be sequenced with HiFi sequencing technology. It will also increase the Revio system’s output, which together with improved analysis methods, enables customers to reduce their sequencing cost per genome by up to 50 percent.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- PacBio includes Onso platform in 10x Genomics Compatible Partner Program
- Tesla lower after ‘underwhelming’ robotaxi launch event: Morning Buzz
- PacBio enters research collaboration with National Cancer Centre of Singapore
- PacBio, A*STAR and Macrogen launch genomics lab in Singapore
- Cathie Wood’s ARK Investment buys 1.2M shares of PacBio today